Ricky Lijing Sun
Partner at Bain Capital
Greater Boston
Overview
Work Experience
Partner, Bain Capital
2020 - Current
Managing Director, Bain Capital Life Sciences
2018 - 2020
Principal, Bain Capital Life Sciences
2016 - 2018
Bain Capital is an alternative investment firm specializing in private equity, venture capital, and credit products.
Member Board of Directors
2022
Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders.
Raised $300,000,000.00 from Paragon Biosciences, Fidelity, Valor Equity Partners and Bain Capital Life Sciences.
Board Member
2022
Board Member
2021
Board Member
2019
Savara Pharmaceuticals develops an inhaled antibiotic for MRSA infection in cystic fibrosis.
Raised $414,100,000.00 from First Light Asset Management, Nantahala Capital Management, Wellington Management, Frazier Life Sciences, TCG Crossover, Bain Capital Life Sciences, Farallon Capital Management and Bain Capital Life Sciences.
Board Of Directors
2018 - 2022
Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Raised $633,999,999.00 from Satter Investment Management, Fairmount Funds Management, Driehaus Capital Management, Adage Capital Management, Venrock Healthcare Capital Partners, Bain Capital Life Sciences and Redmile Group.
Board Of Directors
2018 - 2021
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Raised $833,500,000.00 from SLR Capital Partners.
Board Observer
2019 - 2021
Board Observer
2017 - 2018
Director of Corporate Development & Strategy
2015 - 2016
- Led technical, commercial & financial analyses of multiple M&A opportunities. Partnered with BD to construct key terms in deal / term sheet negotiations for both in-licensing and M&A - Led TA strategy development in neurology and non-malignant hematology by providing commercial point of view for existing and new disease areas of growth for the company - Collaborated with New Product Commercialization team by recommending and defending robust methodologies and frameworks for effectively communicating opportunity assessments.
Associate Director Commercial Assessment and Disease Strategy
2013 - 2014
Business development, in-licensing, M&A, corporate disease strategy
Biogen is a biotechnology company engaged in the development of innovative therapies for neurological and neurodegenerative diseases.